

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 May 2002 (10.05.2002)

PCT

(10) International Publication Number
WO 02/36542 A1

- (51) International Patent Classification⁷: C07C 217/74 (74) Common Representative: CIBA SPECIALTY CHEMICALS HOLDING INC.; Patentabteilung, Klybeckstrasse 141, CH-4057 Basel (CH).
- (21) International Application Number: PCT/EP01/12240
- (22) International Filing Date: 23 October 2001 (23.10.2001) (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
00811014.0 31 October 2000 (31.10.2000) EP
- (71) Applicant (*for all designated States except US*): CIBA SPECIALTY CHEMICALS HOLDING INC. [CH/CH]; Klybeckstrasse 141, CH-4057 Basel (CH).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): VAN DER SCHAAF, Paul, Adriaan [NL/CH]; Marsstrasse 17, CH-4123 Allschwill (CH). MARCOLLI, Claudia [CH/CH]; Heinrichstrasse 210, CH-8005 Zürich (CH). SZELAGIEWICZ, Martin [CH/CH]; Christoph-Merian-Strasse 1, CH-4142 Münchenstein (CH). FREIERMUTH, Beat [CH/FR]; 14, rue du Vignoble, F-68220 Buschwiller (FR).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/36542 A1


(54) Title: CRYSTALLINE FORMS OF VENLAFAXINE HYDROCHLORIDE

(57) Abstract: Crystalline forms of Venlafaxine hydrochloride were found, referred to hereinafter as polymorphic Forms A, B and D. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.

CRYSTALLINE FORMS OF VENLAFAXINE HYDROCHLORIDE

The present invention is directed to crystalline forms of Venlafaxine hydrochloride, processes for their preparation and pharmaceutical compositions comprising these crystalline forms.

The present invention relates to crystalline forms of Venlafaxine hydrochloride. Venlafaxine hydrochloride is known by the chemical name 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride. Venlafaxine hydrochloride has the following formula:



Venlafaxine is an anti-depressant and acts by inhibiting synaptosomal uptake of norepinephrine (3H-NE) and serotonin (14C-5HT). Processes for the preparation of Venlafaxine hydrochloride are described in EP-A-112,669 and in Yardley et al., J. Med. Chem., 1990, vol. 33, page 2899. This hydrochloride salt is desirable since it enables Venlafaxine to be conveniently formulated. There is still a need to produce Venlafaxine in a reproducible, pure and crystalline form to enable formulations to meet exacting pharmaceutical requirements and specifications. Furthermore, it is economically desirable that the product is stable for extended periods of time without the need for specialised storage conditions. The processes in the above mentioned patent and publication result in the preparation of a crystalline form of Venlafaxine hydrochloride having a melting point between 215 and 217°C which is herein designated as Form C. Surprisingly, there have now been found several novel crystalline forms of Venlafaxine hydrochloride, herein designated as Form A and B, and a new crystalline hydrate of Venlafaxine hydrochloride, herein designated as Form D. The novel forms of the present invention have a good thermal stability and/or good solubility characteristics. An additional advantage of Form B is that this form is thermodynamically more stable than the previous known Form C.

Accordingly, the present invention is directed to the following polymorphic Forms A, B and D of Venlafaxine hydrochloride:

A crystalline polymorph of 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 15.3 (vw), 11.9 (w), 9.6 (w), 9.1 (vw), 8.1 (vw), 7.7 (w), 6.3 (vw), 6.0 (m), 5.92 (m), 5.55 (m), 5.46 (vw), 5.20 (m), 5.00 (w), 4.91 (vw), 4.77 (m), 4.57 (s), 4.49 (s), 4.31 (s), 4.26 (s), 4.04 (vw), 3.98 (vw), 3.90 (vw), 3.82 (w), 3.68 (vw), 3.60 (w), 3.52 (w), 3.45 (vw), 3.33 (m), 3.29 (m), 3.22 (vw), 3.15 (vw), 3.07 (vw), 2.87 (vw), 2.81 (w), 2.72 (vw), 2.58 (vw), 2.51 (vw), 2.49 (vw), 2.43 (vw), 2.35 (vw);

herein designated as Form A. Here and in the following the abbreviations in brackets mean: (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; (w) = weak intensity; (vw) = very weak intensity; and (sh) = shoulder.

A crystalline polymorph of 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride which has characteristic Raman bands, expressed in wave number (cm⁻¹): 3075 (m), 3059 (m), 3014 (s), 3000 (m), 2938 (vs), 2915 (s), 2900 (sh), 2863 (m), 2835 (m), 1613 (s), 1583 (w), 1464 (m), 1447 (m), 1273 (m), 1238 (m), 1201 (s), 1181 (s), 1142 (m), 1084 (w), 1062 (w), 1045 (m), 984 (m), 974 (m), 961 (w), 863 (m), 849 (s), 839 (s), 818 (s), 739 (m), 722 (m), 662 (w), 636 (m), 498 (w), 454 (w), 417 (m), 372 (w), 221 (m); herein designated as Form A.

A crystalline polymorph of 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 13.0 (w), 8.6 (s), 6.5 (m), 5.86 (w), 5.71 (s), 5.34 (vw), 5.22 (vw), 5.11 (vw), 4.85 (m), 4.48 (m), 4.36 (vs), 4.08 (s), 3.90 (m), 3.70 (vw), 3.50 (vw), 3.47 (w), 3.35 (vw), 3.27 (w), 3.23 (vw), 3.16 (w), 3.10 (vw), 3.04 (vw), 3.00 (vw), 2.86 (w), 2.83 (vw), 2.76 (vw), 2.73 (vw), 2.71 (vw), 2.62 (vw), 2.55 (m), 2.48 (vw), 2.43 (vw), 2.39 (vw), 2.34 (vw); herein designated as Form B.

A crystalline polymorph of 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at

11.7 (s), 10.2 (w), 7.7 (vw), 6.8 (m), 5.90 (vs), 5.67 (w), 5.57 (vw), 5.37 (m), 5.04 (w), 4.91 (vw), 4.76 (m), 4.70 (m), 4.53 (w), 4.47 (w), 4.42 (vw), 4.32 (m), 4.14 (m), 4.10 (w), 3.95 (vw), 3.84 (w), 3.77 (vw), 3.68 (w), 3.60 (vw), 3.50 (w), 3.35 (m), 3.28 (w), 3.15 (w), 3.07 (vw), 3.04 (vw), 3.01 (vw), 2.93 (w), 2.84 (w), 2.77 (vw), 2.72 (w), 2.68 (vw), 2.63 (w), 2.59 (w), 2.46 (vw), 2.37 (vw), 2.35 (vw), 2.31 (vw), 2.27 (vw), 2.26 (vw);
herein designated as Form D.

A crystalline polymorph of 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride which has characteristic Raman bands, expressed in wave number (cm^{-1}):
3082 (w), 3058 (m), 3022 (m), 2998 (w), 2972 (m), 2953 (s), 2938 (vs), 2916 (m), 2899 (m), 2865 (m), 2856 (m), 2835 (m), 1616 (vs), 1584 (w), 1472 (m), 1452 (m), 1440 (m), 1322 (w), 1303 (w), 1268 (m), 1254 (w), 1241 (w), 1202 (m), 1182 (s), 1143 (w), 1078 (w), 1062 (w), 1044 (w), 980 (m), 973 (w), 862 (w), 848 (s), 840 (s), 817 (vs), 738 (w), 723 (w), 661 (w), 637 (m), 417 (m), 375 (w), 277 (w), 224 (m), 178 (w);
herein designated as Form D.

Known Form C exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (\AA) at
12.9 (w), 10.5 (w), 8.6 (vw), 6.9 (s), 6.5 (m), 5.66 (w), 5.52 (w), 5.41 (m), 5.25 (w), 5.10 (w), 4.67 (s), 4.47 (w), 4.34 (vs), 4.18 (vs), 4.07 (m), 3.99 (vw), 3.87 (vw), 3.69 (vw), 3.55 (m), 3.51 (vw), 3.46 (w), 3.39 (w), 3.32 (vw), 3.26 (w), 3.12 (m), 3.09 (w), 2.94 (vw), 2.88 (w), 2.83 (m), 2.75 (vw), 2.73 (vw), 2.69 (w), 2.64 (m), 2.55 (m), 2.48 (vw), 2.46 (vw), 2.43 (vw), 2.38 (w), 2.35 (vw), 2.32 (w), 2.30 (w), 2.26 (vw).

A discussion of the theory of X-ray powder diffraction patterns can be found in "X-ray diffraction procedures" by H.P. Klug and L.E. Alexander, J. Wiley, New York (1974).

Furthermore, the present invention is directed to processes for the preparation of Forms A, B and D. In addition, the present invention is directed to processes for the preparation of highly pure crystalline Form B. Highly pure Form B is to be understood having a content of this form of 95% by weight, especially 97.5% by weight and preferably 99% by weight.

Form A can be prepared by heating Form C to a temperature just above its melting point (for example 1 to 20°C, especially 1 to 10°C above its melting point) in order to form crystals of Form A.

Form B can be prepared by equilibrating a slurry of polymorphic Form C in an organic solvent, preferably an alcoholic or ketone solvent, especially isopropanol, and separating Form B. The process can be performed with or without the addition of seeding crystals. The addition of seeding crystals is preferred.

Alternatively, Form B can be prepared by dissolving Venlafaxine hydrochloride in an organic solvent, preferably isopropanol, at elevated temperature (for example 40 to 80°C, especially 50 to 70°C) and subsequent cooling. It is preferred to cool to room temperature. The concentration of Venlafaxine hydrochloride is for example 5 to 20 % by weight, especially 10 to 15 % by weight. The cooling rate can vary and is for example 0.1 to 2°C per minute, especially 0.1 to 0.5°C per minute. Preferably, seeding crystals of Form B are added, especially within the metastable zone width, for example at 1 to 10°C, especially 1 to 3°C below the temperature of complete dissolution. The quantity of added seeding crystals is for example 2 to 10 % and especially 10 % of the quantity of Venlafaxine hydrochloride. The seeding crystals are preferably ground before the addition.

Form D can be prepared by evaporating an aqueous solution of Venlafaxine hydrochloride. Preferably evaporation is carried out at a temperature of 10 to 60°C, most preferably at 20 to 40°C, especially at room temperature. It is preferred to carry out evaporation in air.

The preparation of crystalline polymorphic Forms A, B and D is usually carried out by using Form C as the starting compound.

Form C can, for example, be obtained by preparing a solution of Venlafaxine hydrochloride in isopropanol at elevated temperature (for example 40 to 80°C, especially 50 to 70°C) and subsequent cooling of the solution (for example to 0 to 20°C, especially to about 0°C). Precipitated Form C can then be separated.

Another object of the present invention are pharmaceutical compositions comprising an effective amount of crystalline polymorphic Form A, B or D, and a pharmaceutically acceptable carrier.

The polymorphic forms may be used as single components or mixtures.

As to pharmaceutical compositions of Venlafaxine hydrochloride it is preferred that these contain 25-100% by weight, especially 50-100% by weight, of at least one of the novel forms, based on the total amount of Venlafaxine hydrochloride. Preferably, such an amount of the novel polymorphic forms of Venlafaxine hydrochloride is 75-100% by weight, especially 90-100% by weight. Highly preferred is an amount of 95-100% by weight.

The following Examples illustrate the invention in more detail. Temperatures are given in degrees Celsius, parts and percentages are by weight, unless otherwise stated.

Example 1: Preparation of polymorphic Form C

100 parts of Venlafaxine hydrochloride are dissolved in 1600 parts of isopropanol at a temperature of 60°C and subsequently cooled to a temperature of 0°C. This leads to the precipitation of Form C. X-ray powder diffraction studies show the product to be polymorphic Form C (see Fig. 1).

Example 2: Preparation of polymorphic Form A

Form C of Venlafaxine hydrochloride is heated just above its melting point. Newly formed crystals of Form A start to grow out of this melt. X-ray powder diffraction studies show the product to be polymorphic Form A (see Fig. 2). A Raman spectrum of Form A is given in Fig. 3.

Example 3: Preparation of polymorphic Form B

A slurry of 100 parts of Form C of Venlafaxine hydrochloride in 800 parts of isopropanol is equilibrated for 3 days. Subsequent filtration and drying gives pure Venlafaxine hydrochloride Form B. X-ray powder diffraction studies show the product to be polymorphic Form B (see Fig. 4).

Example 4: Preparation of polymorphic Form D

80 parts of Form C of Venlafaxine hydrochloride are dissolved in 500 parts of water. The solution is evaporated in air at room temperature. This gives Venlafaxine hydrochloride Form D. X-ray powder diffraction studies show the product to be polymorphic Form D (see Fig. 5). A Raman spectrum of Form D is given in Fig. 6.

Example 5: Preparation of polymorphic Form B

100 parts of Form C of Venlafaxine hydrochloride are dissolved in 800 parts of isopropanol at 70°C. At 63°C 10 parts of ground Form B of Venlafaxine hydrochloride are added as seeding crystals. The temperature is lowered with a cooling rate of 0.1°C per minute to room temperature. Subsequent filtration and drying gives pure Venlafaxine hydrochloride Form B.

Brief description of the drawings

Figure 1 is a characteristic X-ray powder diffraction pattern for Form C

Figure 2 is a characteristic X-ray powder diffraction pattern for Form A

Figure 3 is a characteristic Raman spectrum of Form A

Figure 4 is a characteristic X-ray powder diffraction pattern for Form B

Figure 5 is a characteristic X-ray powder diffraction pattern for Form D

Figure 6 is a characteristic Raman spectrum of Form D

Claims

1. A crystalline polymorph of 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at
15.3 (vw), 11.9 (w), 9.6 (w), 9.1 (vw), 8.1 (vw), 7.7 (w), 6.3 (vw), 6.0 (m), 5.92 (m), 5.55 (m), 5.46 (vw), 5.20 (m), 5.00 (w), 4.91 (vw), 4.77 (m), 4.57 (s), 4.49 (s), 4.31 (s), 4.26 (s), 4.04 (vw), 3.98 (vw), 3.90 (vw), 3.82 (w), 3.68 (vw), 3.60 (w), 3.52 (w), 3.45 (vw), 3.33 (m), 3.29 (m), 3.22 (vw), 3.15 (vw), 3.07 (vw), 2.87 (vw), 2.81 (w), 2.72 (vw), 2.58 (vw), 2.51 (vw), 2.49 (vw), 2.43 (vw), 2.35 (vw);
wherein (s) = strong intensity; (m) = medium intensity; (w) = weak intensity; and (vw) = very weak intensity.
2. A crystalline polymorph of 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride which has characteristic Raman bands, expressed in wave number (cm⁻¹):
3075 (m), 3059 (m), 3014 (s), 3000 (m), 2938 (vs), 2915 (s), 2900 (sh), 2863 (m), 2835 (m), 1613 (s), 1583 (w), 1464 (m), 1447 (m), 1273 (m), 1238 (m), 1201 (s), 1181 (s), 1142 (m), 1084 (w), 1062 (w), 1045 (m), 984 (m), 974 (m), 961 (w), 863 (m), 849 (s), 839 (s), 818 (s), 739 (m), 722 (m), 662 (w), 636 (m), 498 (w), 454 (w), 417 (m), 372 (w), 221 (m);
wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; (w) = weak intensity; and (sh) = shoulder.
3. A crystalline polymorph of 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at
13.0 (w), 8.6 (s), 6.5 (m), 5.86 (w), 5.71 (s), 5.34 (vw), 5.22 (vw), 5.11 (vw), 4.85 (m), 4.48 (m), 4.36 (vs), 4.08 (s), 3.90 (m), 3.70 (vw), 3.50 (vw), 3.47 (w), 3.35 (vw), 3.27 (w), 3.23 (vw), 3.16 (w), 3.10 (vw), 3.04 (vw), 3.00 (vw), 2.86 (w), 2.83 (vw), 2.76 (vw), 2.73 (vw), 2.71 (vw), 2.62 (vw), 2.55 (m), 2.48 (vw), 2.43 (vw), 2.39 (vw), 2.34 (vw);
wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; (w) = weak intensity; and (vw) = very weak intensity.

4. A crystalline polymorph of 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at

11.7 (s), 10.2 (w), 7.7 (vw), 6.8 (m), 5.90 (vs), 5.67 (w), 5.57 (vw), 5.37 (m), 5.04 (w), 4.91 (vw), 4.76 (m), 4.70 (m), 4.53 (w), 4.47 (w), 4.42 (vw), 4.32 (m), 4.14 (m), 4.10 (w), 3.95 (vw), 3.84 (w), 3.77 (vw), 3.68 (w), 3.60 (vw), 3.50 (w), 3.35 (m), 3.28 (w), 3.15 (w), 3.07 (vw), 3.04 (vw), 3.01 (vw), 2.93 (w), 2.84 (w), 2.77 (vw), 2.72 (w), 2.68 (vw), 2.63 (w), 2.59 (w), 2.46 (vw), 2.37 (vw), 2.35 (vw), 2.31 (vw), 2.27 (vw), 2.26 (vw);

wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; (w) = weak intensity; and (vw) = very weak intensity.

5. A crystalline polymorph of 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride which has characteristic Raman bands, expressed in wave number (cm⁻¹):

3082 (w), 3058 (m), 3022 (m), 2998 (w), 2972 (m), 2953 (s), 2938 (vs), 2916 (m), 2899 (m), 2865 (m), 2856 (m), 2835 (m), 1616 (vs), 1584 (w), 1472 (m), 1452 (m), 1440 (m), 1322 (w), 1303 (w), 1268 (m), 1254 (w), 1241 (w), 1202 (m), 1182 (s), 1143 (w), 1078 (w), 1062 (w), 1044 (w), 980 (m), 973 (w), 862 (w), 848 (s), 840 (s), 817 (vs), 738 (w), 723 (w), 661 (w), 637 (m), 417 (m), 375 (w), 277 (w), 224 (m), 178 (w);

wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; and (w) = weak intensity.

6. A process for the preparation of a crystalline polymorph according to claim 1 or 2, which comprises heating polymorphic Form C to a temperature just above its melting point in order to form crystals of the crystalline polymorph according to claim 1 or 2.

7. A process for the preparation of a crystalline polymorph according to claim 3, which comprises dissolving Venlafaxine in an organic solvent, preferably isopropanol, to form a solution at elevated temperature, adding seeding crystals, cooling the solution, and separating the crystalline polymorph according to claim 3.

8. A process according to claim 7, wherein the seeding crystals are ground before addition to the solution.

9. A process for the preparation of a crystalline polymorph according to claim 3, which comprises equilibrating a slurry of polymorphic Form C in isopropanol and separating the crystalline polymorph according to claim 3.
10. A process for the preparation of a crystalline polymorph according to claim 4 or 5, which comprises evaporating or lyophilisation of an aqueous solution of 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride.
11. A pharmaceutical composition comprising an effective amount of a crystalline polymorphic form according to any of claims 1 to 5, and a pharmaceutically acceptable carrier.

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5





Fig. 6



INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 01/12240

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07C217/74

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	YARDLEY J P ET AL: "2-PHENYL-2-(1-HYDROXYCYCLOALKYL)ETHYLAMIN E DERIVATIVES: SYNTHESIS AND ANTIDEPRESSANT ACTIVITY" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 33, 1990, pages 2899-2905, XP000891765 ISSN: 0022-2623 cited in the application * table 1, compounds 4, (+)-4, (-)-4 * * page 2903, synthesis of compound (4) *	1-11
A	EP 0 444 855 A (LILLY CO ELI) 4 September 1991 (1991-09-04) claims	1-11

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

8 February 2002

Date of mailing of the international search report

18/02/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

O'Sullivan, P

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/12240

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0444855	A	04-09-1991	
		AU 7190791 A	29-08-1991
		CA 2037239 A1	29-08-1991
		CN 1054418 A	11-09-1991
		EP 0444855 A1	04-09-1991
		FI 910897 A	29-08-1991
		HU 60711 A2	28-10-1992
		IE 910666 A1	28-08-1991
		JP 4211638 A	03-08-1992
		NO 910782 A	29-08-1991
		PT 96882 A	31-10-1991
		US 5250571 A	05-10-1993
		ZA 9101406 A	25-11-1992